“Building Combinations: What are the Novel Ideas?” was moderated by Li Watsek and Brandon Folkes, CFA. It featured Jaume Pons, CEO of ALX Oncology, Michael Bailey, President & CEO of AVEO Oncology, Steve Worland, CEO of eFFECTOR Therapeutics, Inc., and Jeremy Graff, PhD, CSO of IMV Inc.

• ALXO spoke about the applicability of evorpacept (anti-CD47) in combination treatments for gastric and head-and-neck cancers. The company noted that from data thus far, evorpacept combos have beaten benchmarks for response rate and survival in both of these indications, and the key is to have randomized data.

• eFFECTOR is working on a new cancer therapy that blocks the translation of messenger RNA and currently has two compounds in phase 2 trials.

• IMV discussed its unique DPX technology that gives it the ability to create a new class of immunotherapy to improve cancer treatment.

• Aveo Oncology is a commercial stage oncology company, which commercialized its first product in 1Q2021 and has a deep pipeline.

#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare